Restructuring	12 Months Ended
Dec. 31, 2017
Restructuring and Related Activities [Abstract]
Restructuring	Restructuring In December 2017, in conjunction with the Divestiture (see Note 2, “Discontinued Operations”), we initiated the initial phase of a multi-year restructuring plan (the “Plan”). The initial phase of the Plan is intended to align our organizational and management structure with our remaining Medical Devices business. We expect to incur between $8 million and $10 million of pre-tax costs, of which $6 million to $7 million is for employee severance and benefits and the remainder for third-party services and other related costs. These are cash costs that will be incurred as we execute the Plan, which we expect to substantially complete by the end of 2019. We have incurred $5 million of costs, primarily for employee severance and benefits. These costs are included in “Cost of products sold” and “Selling and general” expenses in the accompanying consolidated income statement for the year ended December 31, 2017. For the year ended December 31, 2017, no severance and benefits payments have been made and the remaining liability in “Accrued expenses” and “Other long-term liabilities” for employee severance and benefits was $5 million in the accompanying consolidated balance sheet as of December 31, 2017.

Restructuring

In December 2017, in conjunction with the Divestiture (see Note 2, “Discontinued Operations”), we initiated the initial phase of a multi-year restructuring plan (the “Plan”). The initial phase of the Plan is intended to align our organizational and management structure with our remaining Medical Devices business.

We expect to incur between $8 million and $10 million of pre-tax costs, of which $6 million to $7 million is for employee severance and benefits and the remainder for third-party services and other related costs. These are cash costs that will be incurred as we execute the Plan, which we expect to substantially complete by the end of 2019.

We have incurred $5 million of costs, primarily for employee severance and benefits. These costs are included in “Cost of products sold” and “Selling and general” expenses in the accompanying consolidated income statement for the year ended December 31, 2017. For the year ended December 31, 2017, no severance and benefits payments have been made and the remaining liability in “Accrued expenses” and “Other long-term liabilities” for employee severance and benefits was $5 million in the accompanying consolidated balance sheet as of December 31, 2017.